Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML projectClaudia Sargas, Pau Montesinos, Rosa Ayala et al.|Haematologica|2020Cited by 37
<scp>First‐in‐human</scp> study of <scp>JNJ</scp>‐63709178, a <scp>CD123</scp>/<scp>CD3</scp> targeting antibody, in relapsed/refractory acute myeloid leukemiaMichael Boyiadzis, Juan Manuel Alonso‐Domínguez, Pinkal Desai et al.|Clinical and Translational Science|2022Cited by 35
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA RegistryClaudia Sargas, Rosa Ayala, María José Larráyoz et al.|Cancers|2023Cited by 30
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA groupClaudia Sargas, Rosa Ayala, María José Larráyoz et al.|Blood Cancer Journal|2023Cited by 28
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimensTamara Castaño-Bonilla, Pau Montesinos, Juan Manuel Alonso‐Domínguez et al.|Scientific Reports|2021Cited by 25